Profile of palbociclib in the treatment of metastatic breast cancer

Moataz Ehab,1 Mohamad Elbaz2,31Department of Pharmacy Practice, 2Department of Pharmacology, Pharmacy School, Helwan University, Egypt; 3Department of Pathology, The Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH, USAAbstract: Breast cancer is the...

Full description

Bibliographic Details
Main Authors:	Ehab M, Elbaz M
Format:	Article
Language:	English
Published:	Dove Medical Press 2016-05-01
Series:	Breast Cancer: Targets and Therapy
Subjects:	Cyclin Dependent kinases cell cycle metastatic breast cancer PD0332991
Online Access:	https://www.dovepress.com/profile-of-palbociclib-in-the-treatment-of-metastatic-breast-cancer-peer-reviewed-article-BCTT

Similar Items

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
by: Eric Raspé, et al.
Published: (2017-08-01)

Response to Abemaciclib After 10 Lines of Therapy Including Palbociclib in Metastatic Breast Cancer: A Case Report With Literature Review
by: Isabella O. Wender, et al.
Published: (2020-09-01)

Recent Progress of Palbociclib in Treatment of HR+/HER2- Breast Cancer
by: ZHENG Fangchao, et al.
Published: (2022-07-01)

Ribociclib in the first-line therapy for metastatic hormone-dependent HER2-negative breast cancer in patients with intact ovarian function
by: S. F. Menshikova, et al.
Published: (2018-11-01)

Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study
by: Masato Takahashi, et al.
Published: (2020-07-01)

Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors
by: Pauline Rottier, et al.
Published: (2023-01-01)

Role of PD 0332991 on the Proliferation and Apoptosis of Vascular Endothelial Cells
by: Chenlong ZHAO, et al.
Published: (2018-05-01)

Synergism of Cyclin-Dependent Kinase Inhibitors with Camptothecin Derivatives in Small Cell Lung Cancer Cell Lines
by: Gerhard Hamilton, et al.
Published: (2014-02-01)

Palbociclib-mediated cell cycle arrest can occur in the absence of the CDK inhibitors p21 and p27
by: Betheney R. Pennycook, et al.
Published: (2021-11-01)

Safety of CDK4/6 Inhibitors Combined with Radiotherapy in Patients with Metastatic Breast Cancer: A Review of the Literature
by: Rejane Franco, et al.
Published: (2023-06-01)

Capecitabine efficacy after cycline-dependent-kinase 4/6 inhibitor plus endocrine therapy in metastatic hormone receptor-positive breast cancer
by: L. Bender, et al.
Published: (2023-01-01)

Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
by: Mónica Cejuela, et al.
Published: (2023-05-01)

Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
by: Michela Piezzo, et al.
Published: (2020-09-01)

Cyclin-dependent kinase inhibitors: efficacy and safety
by: I. B. Kononenko, et al.
Published: (2019-06-01)

HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study
by: Francesca Carlino, et al.
Published: (2022-10-01)

Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
by: Navid Sobhani, et al.
Published: (2019-04-01)

Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments
by: Hideki Nawa, et al.
Published: (2022-01-01)

Real-world treatment patterns of subsequent therapy after palbociclib in patients with advanced breast cancer in Japan
by: Masataka Sawaki, et al.
Published: (2023-08-01)

Correlation of serum concentration cyclin-dependent kinase 4 and cyclin-dependent kinase 6 with breast cancer in Babylon province
by: Dalya Shakir Al-Owaidi, et al.
Published: (2020-01-01)

Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
by: Iorfida M, et al.
Published: (2020-03-01)

A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors
by: Mariane Teodoro Fernandes, et al.
Published: (2018-11-01)

CDK4/6 inhibitor PD0332991 in glioblastoma treatment: does it have a future?
by: Lisette eSchroder, et al.
Published: (2015-11-01)

CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions
by: Rossana Roncato, et al.
Published: (2020-09-01)

Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2− Metastatic Breast Cancer: A Podcast
by: Brian Dong, et al.
Published: (2023-09-01)

Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2− metastatic breast cancer: a focus on ribociclib
by: Edessa D, et al.
Published: (2017-12-01)

Palbociclib in metastatic breast cancer: current evidence and real-life data
by: Francesco Serra, et al.
Published: (2019-07-01)

CDKs family -a glimpse into the past and present: from cell cycle control to current biological functions
by: Muzna Shah, et al.
Published: (2020-02-01)

Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development–Review
by: Paweł Łukasik, et al.
Published: (2021-03-01)

Regression of choroidal metastasis from breast carcinoma with palbociclib
by: Shweta Parakh, et al.
Published: (2022-08-01)

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer
by: Kamila Kaminska, et al.
Published: (2021-02-01)

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer
by: Tarah J. Ballinger, et al.
Published: (2018-08-01)

Sub-cloning of cyclin-dependent kinase 3 (CDK3) gene into a mammalian expression vector /
by: Alnaseri, Zubaida Talal M., 1996-, author 614711
Published: (2018)

The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations
by: Xavier Bisteau, et al.
Published: (2014-01-01)

Il ciclo cellulare: cos'è, come è stato e come sarà studiato
by: Sara Nardi, et al.
Published: (2015-06-01)

Sub-cloning of cyclin-dependent kinase 3 (CDK3) gene into a mammalian expression vector /
by: Alnaseri, Zubaida Talal M., 1996-, author 614711, et al.
Published: (2018)

Palbociclib in the first line combination hormone therapy of HER2- negative metastatic hormone-dependent breast cancer. Clinical follow-up
by: M. A. Frolova, et al.
Published: (2018-07-01)

Oncogenic and Tumor Suppressive Components of the Cell Cycle in Breast Cancer Progression and Prognosis
by: Dharambir Kashyap, et al.
Published: (2021-04-01)

Efficacy and safety of cyclin‐dependent kinase 4/6 inhibitor in patients with advanced breast cancer: A real‐world experience
by: Tzu‐Rong Peng, et al.
Published: (2023-10-01)

Policing Cancer: Vitamin D Arrests the Cell Cycle
by: Sachin Bhoora, et al.
Published: (2020-12-01)

Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer
by: April C. Watt, et al.
Published: (2022-03-01)